Autologous adipose derived mesenchymal stem cells - Hope Biosciences
Alternative Names: Autologous HB-adMSCs; HB adMSCs; HB-adMSCLatest Information Update: 15 Apr 2025
At a glance
- Originator Hope Biosciences
- Developer Hope Biosciences; University of Texas Health Science Center at Houston
- Class Antineoplastics; Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections; Juvenile rheumatoid arthritis; Multiple sclerosis
- Phase I/II Alzheimer's disease; Musculoskeletal pain; Rheumatoid arthritis; Traumatic brain injuries
- No development reported Cerebral palsy; Glioblastoma; Huntington's disease; Osteoarthritis; Parkinson's disease; Prostate cancer; Spinal cord injuries; Stroke; Thrombotic thrombocytopenic purpura
Most Recent Events
- 01 Apr 2025 Hope Biosciences initiates enrolment in a phase-II trial for Multiple sclerosis in USA (IV) (NCT06800404)
- 28 Mar 2025 No recent reports of development identified for preclinical development in Glioblastoma in USA (IV)
- 05 Mar 2025 Phase-II clinical trials in Juvenile rheumatoid arthritis (In children, In adolescents) in USA (IV)